BTLA and non-small cell lung carcinoma: Clinically, several trials are evaluating the anti-BTLA antibody tifcemalimab (JS004/icatolimab), alone or in combination with the PD-1 inhibitor toripalimab, across malignancies such as Hodgkin lymphoma, NSCLC, SCLC, and ESCC (Table 3).